Am J Med Sci . Hyperlipidemia, COVID-19 and acute pancreatitis: a tale of three entities

[tetano]

Am J Med Sci


. 2022 Apr 2;S0002-9629(22)00132-X.
doi: 10.1016/j.amjms.2022.03.007. Online ahead of print.
Hyperlipidemia, COVID-19 and acute pancreatitis: a tale of three entities


Qiuyi Tang ¹ , Lin Gao ² , Zhihui Tong ³ , Weiqin Li ⁴



Affiliations

• PMID: 35381217
• DOI: 10.1016/j.amjms.2022.03.007

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) caused the ongoing pandemic of coronavirus disease 2019 (COVID-19), which presented as not only respiratory symptoms, but various digestive manifestations have also been recognized, including pancreatic injury and acute pancreatitis (AP). The underlying mechanism is still unclear. Hypertriglyceridemia has become one of the leading causes of AP in recent years and hyperlipidemia is highly reported in COVID-19 cases. The current narrative review aimed to explore the associations between AP, COVID-19 and hyperlipidemia. Substantial cases of COVID-19 patients complicated with AP were reported, while the incidence of AP in the COVID-19 population was relatively low. Hyperlipidemia was common in COVID-19 patients with a pooled incidence of 32.98%. Hyperlipidemia could be a mediating factor in the pathogenesis of AP in COVID-19 patients. Further studies are warranted to clarify the relationship among AP, lipid metabolism disorders and COVID-19.

Keywords: COVID-19; SARS-CoV-2; acute pancreatitis; hyperlipidemia; pancreatic injury.